Breakthrough Therapies: Market Dynamics and Investment Opportunities
Report Scope
This report examines the potential risks and benefits of receiving breakthrough therapy designation (BTD), compares and contrasts fast-track drug development approaches (logistics, criteria and implications), and highlights the opportunities and challenges of creating breakthrough therapies. Cardiovascular, central nervous systems and neurology, rare diseases, oncology and other diseases are among the therapy areas in which this report analyzes BTD. It also examines leading companies, approved and pending products, and product revenues. It examines BTD’s achievements and shortcomings and discusses the tactics organizations use to optimize BTD’s competitive edge.
To provide an in-depth understanding of the market, this report also includes profiles of market participants, the competitive landscape, key competitors and respective market share.
The market in this report is divided into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.
Report Includes
26 data tables and 49 additional tables
An overview of the global market dynamics and investment opportunities for breakthrough therapy designation (BTD) drugs
Analyses of the global market trends, with sales data for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
Evaluation and forecast the market size for breakthrough therapies based on type, and geographical region
Discussion of emerging technologies and developments and various macroeconomic factors affecting the breakthrough therapies market
Review of patent data and new developments regarding various categories and sub-categories of breakthrough therapies
A discussion on ESG challenges and practices of the industry
Assessment of the vendor landscape, including the market shares of leading companies, their product portfolios and financial overviews
Information on recent mergers, acquisitions, expansions, collaborations, investments, divestments, product launches, and other strategic developments
Profiles of the leading market vendors, including F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Co., Novartis AG and AstraZeneca
Companies Mentioned
ABBVIE INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
VERTEX PHARMACEUTICALS INC.
- Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Chapter 2 Market Overview
- Overview
- Porter's Five Forces Analysis
- Potential for New Entrants: High
- Bargaining Power of Suppliers: Medium
- Bargaining Power of Buyers: Medium
- Threat of Substitute Products: High
- Industry Competition: High
- PESTEL Analysis of the Pharmaceutical Industry
- Political Factors
- Economic Factors
- Social Factors
- Technological Factors
- Environmental Factors
- Legal Factors
- Impact of Breakthrough Therapy Drugs on Business Growth
- Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- More Drugs Gaining Breakthrough Status
- Expedited Approval Process in the EU
- Increasing Prevalence of Life-Threatening Conditions
- Market Restraints
- Increasing Preference for Generics
- Market Opportunities
- Rising Use of Technologies in Clinical Trials
- Chapter 4 Emerging Trends
- Overview
- Nanotechnology: Enhancing Drug Discovery and Delivery
- Merging Technologies in Drug Discovery
- Conclusion
- Chapter 5 Regulatory Landscape
- Overview
- Policy
- Procedures
- CDER-Sponsor Meetings and Other Communications
- CDER Internal Meetings and Communications
- CDER Review of Breakthrough Therapy Drug Development Programs
- Rescinding a Breakthrough Therapy Designation
- Chapter 6 Market Segmentation Analysis
- Segmentation Breakdown
- Market Breakdown by Therapy
- Cardiovascular
- CNS and Neurology
- Infectious Diseases
- Oncology
- Rare Diseases
- Other Diseases
- Geographic Breakdown
- Market Breakdown by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Chapter 7 Competitive Intelligence
- Overview
- PRIME Designation Lists
- Global Ranks of Leading Companies
- Chapter 8 Sustainability in the BDT Market: An ESG Perspective
- Role of ESG in the Pharma Industry
- Environmental
- Social
- Governance
- ESG Risk Ratings
- Conclusion
- Chapter 9 Appendix
- Methodology
- Abbreviations
- Sources
- Company Profiles
- ABBVIE INC.
- ASTRAZENECA
- BRISTOL-MYERS SQUIBB CO.
- F. HOFFMANN-LA ROCHE LTD.
- JOHNSON & JOHNSON SERVICES INC.
- MERCK & CO. INC.
- NOVARTIS AG
- PFIZER INC.
- REGENERON PHARMACEUTICALS INC.
- VERTEX PHARMACEUTICALS INC.
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook